Targeting APRIL in the Treatment of IgA Nephropathy
Clin J Am Soc Nephrol
.
2024 Mar 1;19(3):394-398.
doi: 10.2215/CJN.0000000000000338.
Epub 2023 Oct 6.
Authors
Chee Kay Cheung
1
2
,
Jonathan Barratt
1
2
,
Kevin Carroll
3
,
Richard A Lafayette
4
,
Adrian Liew
5
,
Yusuke Suzuki
6
,
Vladimír Tesař
7
,
Hernán Trimarchi
8
,
Muh Geot Wong
9
10
,
Hong Zhang
11
,
Vlado Perkovic
12
,
Dana V Rizk
13
Affiliations
1
Department of Cardiovascular Sciences, University of Leicester, Leicester, United Kingdom.
2
John Walls Renal Unit, University Hospitals of Leicester NHS Trust, Leicester, United Kingdom.
3
KJC Statistics, Macclesfield, United Kingdom.
4
Division of Nephrology, Department of Medicine, Stanford University School of Medicine, Stanford University, Stanford, California.
5
The Kidney and Transplant Practice, Mount Elizabeth Novena Hospital, Singapore.
6
Department of Nephrology, Juntendo University Faculty of Medicine, Tokyo, Japan.
7
Department of Nephrology, General University Hospital, Charles University, Prague, Czech Republic.
8
Nephrology Service and Kidney Transplant Unit, Hospital Británico de Buenos Aires, Buenos Aires, Argentina.
9
Concord Repatriation General Hospital, Concord, Australia.
10
University of Sydney, Camperdown, Australia.
11
Renal Division, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, People's Republic of China.
12
University of New South Wales, Sydney, New South Wales, Australia.
13
Division of Nephrology, University of Alabama at Birmingham, Birmingham, Alabama.
PMID:
37801688
PMCID:
PMC10937009
(available on
2025-03-01
)
DOI:
10.2215/CJN.0000000000000338
No abstract available
MeSH terms
Glomerulonephritis, IGA* / drug therapy
Humans
Immunoglobulin A
Substances
Immunoglobulin A